The Laparoscopic Devices Market is propelled by two powerful and commercially transformative Laparoscopic Devices Market Drivers that are reshaping the global surgical landscape: the increasing prevalence of chronic diseases that directly generate demand for laparoscopic surgical intervention, and the rapid expansion of robotic-assisted laparoscopic surgery that is elevating the precision, safety, and clinical scope of minimally invasive procedures. These drivers collectively underpin the market's projected expansion from US$ 13,935.68 million in 2024 to US$ 26,609.70 million by 2031 at a CAGR of 9.7%.

Increasing Prevalence of Chronic Diseases

The increasing global prevalence of chronic diseases that frequently require surgical intervention is the foundational driver of the laparoscopic devices market, with minimally invasive laparoscopic approaches increasingly favored over open surgery across a broad and growing range of surgical indications. The global obesity epidemic is a particularly significant driver, with estimates projecting that by 2025, 167 million people will experience worsened health from being overweight or obese. This directly stimulates demand for laparoscopic bariatric surgery, with laparoscopic sleeve gastrectomy emerging as the dominant surgical weight loss procedure globally. A study conducted from March 2023 through February 2024 in Jeddah, Saudi Arabia demonstrated that 93.3% of 208 bariatric patients underwent laparoscopic sleeve gastrectomy, with significant improvements in BMI and obesity-related comorbidities including hypertension and diabetes.

Request Sample Pages of this Research Study @ https://www.businessmarketinsights.com/sample/BMIPUB00031631

Gallstone disease is another major chronic condition driving laparoscopic procedure volume. A systematic review published in February 2025 estimated global gallstone prevalence at 6.1%, with laparoscopic cholecystectomy remaining the gold standard surgical treatment. A report from May 2025 confirmed that laparoscopic approaches now account for greater than 80% of all cholecystectomies performed globally, delivering shorter recovery times and fewer complications versus open surgery. Colorectal cancer represents an additional significant driver, with GLOBOCAN 2022 data published in February 2025 reporting over 53,941 new colorectal cancer cases in the Eastern Mediterranean Region alone, while the American Cancer Society reported over 107,320 new colon cancer and 46,950 new rectal cancer cases in the United States. These high incidence rates directly drive demand for laparoscopic colorectal surgeries, with advancements in robotic-assisted proctectomy improving surgical precision.

The shift toward laparoscopic appendectomy is equally evident, with a January 2025 report noting increased adoption due to reduced incisions and faster recovery. A February 2025 study published in the International Surgery Journal found that laparoscopic appendectomy patients averaged 1.77 hospital days versus 7.73 days for open appendectomy, with significantly lower pain scores and faster return to normal activity, providing compelling clinical evidence that is accelerating laparoscopic adoption across surgical specialties globally.

Robotic-Assisted Laparoscopic Surgeries

The rapid commercialization and expanding clinical adoption of robotic-assisted laparoscopic surgery represents the most commercially dynamic growth opportunity in the market. Robotic-assisted procedures represented approximately 15% of general surgeries in 2023 and are projected to reach 30% within the next five years, demonstrating the exceptional growth trajectory of this premium technology segment. Adoption is already substantial in specific procedure categories including thyroid cancer surgery at 38% and prostate cancer surgery at 27.8%, with strong and growing adoption in colorectal and cardiothoracic procedures.

In April 2025, Medtronic announced that its Expand URO Investigational Device Exemption clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints in 137 patients undergoing urologic procedures using the Hugo robotic-assisted surgery system. In April 2025, Johnson and Johnson MedTech announced completion of the first cases in the clinical trial for its OTTAVA Robotic Surgical System, with the first clinical experience including a Roux-en-Y gastric bypass surgery, marking a landmark milestone in next-generation surgical robotics development. These concurrent competitive developments from the two largest surgical device companies in the world underscore the massive commercial investment flowing into the robotic-assisted laparoscopic surgery segment.

About Us

Business Market Insights is a one-stop industry research provider of actionable intelligence. Specializing in industries including Manufacturing and Construction, Semiconductor and Electronics, Healthcare, and more, the firm publishes over 500 research reports annually.

Contact Us

If you have any queries about this report or if you would like further information, please contact us: Phone: +16467917070 E-mail: sales@businessmarketinsights.com